Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's innovative TrueGlue platform. Read more here.

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...